Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 361.1 Billion KRW | 6.08% |
| 2022 | 340.42 Billion KRW | 16.18% |
| 2021 | 293.01 Billion KRW | 7.7% |
| 2020 | 272.07 Billion KRW | -11.42% |
| 2019 | 307.15 Billion KRW | 0.18% |
| 2018 | 306.6 Billion KRW | 18.43% |
| 2017 | 258.88 Billion KRW | 9.02% |
| 2016 | 237.47 Billion KRW | 6.39% |
| 2015 | 223.2 Billion KRW | 4.56% |
| 2014 | 213.47 Billion KRW | -3.07% |
| 2013 | 220.24 Billion KRW | -1.4% |
| 2012 | 223.37 Billion KRW | -4.77% |
| 2011 | 234.56 Billion KRW | 8.96% |
| 2010 | 215.27 Billion KRW | 48.35% |
| 2009 | 145.11 Billion KRW | -23.06% |
| 2008 | 188.6 Billion KRW | 7.7% |
| 2007 | 175.11 Billion KRW | 17.74% |
| 2006 | 148.73 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 115.16 Billion KRW | -3.13% |
| 2024 Q1 | 118.88 Billion KRW | 41.13% |
| 2023 Q2 | 89.99 Billion KRW | -9.48% |
| 2023 Q1 | 99.41 Billion KRW | 17.71% |
| 2023 Q4 | 84.24 Billion KRW | -3.68% |
| 2023 Q3 | 87.45 Billion KRW | -2.81% |
| 2023 FY | 361.1 Billion KRW | 6.08% |
| 2022 Q1 | 85.29 Billion KRW | 11.76% |
| 2022 Q3 | 83.45 Billion KRW | -4.31% |
| 2022 Q4 | 84.45 Billion KRW | 1.2% |
| 2022 FY | 340.42 Billion KRW | 16.18% |
| 2022 Q2 | 87.21 Billion KRW | 2.26% |
| 2021 Q1 | 71.82 Billion KRW | 4.6% |
| 2021 FY | 293.01 Billion KRW | 7.7% |
| 2021 Q2 | 75.8 Billion KRW | 5.53% |
| 2021 Q3 | 69.07 Billion KRW | -8.88% |
| 2021 Q4 | 76.31 Billion KRW | 10.49% |
| 2020 Q4 | 68.67 Billion KRW | 3.16% |
| 2020 Q3 | 66.56 Billion KRW | -4.68% |
| 2020 Q2 | 69.83 Billion KRW | 4.22% |
| 2020 FY | 272.07 Billion KRW | -11.42% |
| 2020 Q1 | 67 Billion KRW | -19.6% |
| 2019 Q4 | 83.34 Billion KRW | 12.29% |
| 2019 Q2 | 74.92 Billion KRW | 0.36% |
| 2019 Q1 | 74.66 Billion KRW | 0.0% |
| 2019 FY | 307.15 Billion KRW | 0.18% |
| 2019 Q3 | 74.21 Billion KRW | -0.95% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 FY | 306.6 Billion KRW | 18.43% |
| 2018 Q2 | 79.33 Billion KRW | 3.08% |
| 2018 Q1 | 76.96 Billion KRW | 15.12% |
| 2018 Q3 | 74.91 Billion KRW | -5.57% |
| 2017 Q3 | 64.43 Billion KRW | -3.77% |
| 2017 FY | 258.88 Billion KRW | 9.02% |
| 2017 Q4 | 66.85 Billion KRW | 3.76% |
| 2017 Q1 | 60.64 Billion KRW | 3.9% |
| 2017 Q2 | 66.95 Billion KRW | 10.41% |
| 2016 FY | 237.47 Billion KRW | 6.39% |
| 2016 Q1 | 59.23 Billion KRW | 2.73% |
| 2016 Q2 | 62.51 Billion KRW | 5.54% |
| 2016 Q3 | 57.36 Billion KRW | -8.24% |
| 2016 Q4 | 58.36 Billion KRW | 1.75% |
| 2015 Q1 | 52.4 Billion KRW | -2.11% |
| 2015 Q4 | 57.65 Billion KRW | 3.21% |
| 2015 Q3 | 55.85 Billion KRW | -2.48% |
| 2015 Q2 | 57.28 Billion KRW | 9.31% |
| 2015 FY | 223.2 Billion KRW | 4.56% |
| 2014 Q2 | 57.11 Billion KRW | 14.45% |
| 2014 Q1 | 49.89 Billion KRW | -7.12% |
| 2014 FY | 213.47 Billion KRW | -3.07% |
| 2014 Q4 | 53.53 Billion KRW | 1.13% |
| 2014 Q3 | 52.93 Billion KRW | -7.32% |
| 2013 Q3 | 52.2 Billion KRW | -11.55% |
| 2013 FY | 220.24 Billion KRW | -1.4% |
| 2013 Q1 | 55.3 Billion KRW | -2.78% |
| 2013 Q2 | 59.01 Billion KRW | 6.71% |
| 2013 Q4 | 53.72 Billion KRW | 2.91% |
| 2012 Q4 | 56.88 Billion KRW | 6.06% |
| 2012 Q1 | 54.38 Billion KRW | -4.21% |
| 2012 Q2 | 58.47 Billion KRW | 7.53% |
| 2012 FY | 223.37 Billion KRW | -4.77% |
| 2012 Q3 | 53.62 Billion KRW | -8.29% |
| 2011 FY | 234.56 Billion KRW | 8.96% |
| 2011 Q2 | 60.89 Billion KRW | 0.96% |
| 2011 Q4 | 56.77 Billion KRW | 0.35% |
| 2011 Q1 | 60.31 Billion KRW | 1.76% |
| 2011 Q3 | 56.57 Billion KRW | -7.1% |
| 2010 Q3 | 53.38 Billion KRW | 2.12% |
| 2010 Q4 | 59.27 Billion KRW | 11.03% |
| 2010 Q1 | 50.34 Billion KRW | 0.0% |
| 2010 FY | 215.27 Billion KRW | 48.35% |
| 2010 Q2 | 52.27 Billion KRW | 3.83% |
| 2009 Q2 | 48.02 Billion KRW | -15.22% |
| 2009 Q1 | 56.64 Billion KRW | 29.09% |
| 2009 FY | 145.11 Billion KRW | -23.06% |
| 2009 Q3 | 44.14 Billion KRW | -8.08% |
| 2008 FY | 188.6 Billion KRW | 7.7% |
| 2008 Q3 | 41.15 Billion KRW | -12.3% |
| 2008 Q4 | 43.88 Billion KRW | 6.62% |
| 2008 Q2 | 46.92 Billion KRW | -5.7% |
| 2008 Q1 | 49.76 Billion KRW | 19.01% |
| 2007 Q4 | 41.81 Billion KRW | -4.86% |
| 2007 FY | 175.11 Billion KRW | 17.74% |
| 2007 Q2 | 39.59 Billion KRW | 0.0% |
| 2007 Q3 | 43.95 Billion KRW | 11.01% |
| 2006 FY | 148.73 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -163.18% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 68.1% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 43.44% |
| HANDOK Inc. | 522.74 Billion KRW | 30.92% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -166.751% |
| Yuhan Corporation | 1858.98 Billion KRW | 80.575% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 45.615% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -595.041% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 75.779% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -167.667% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 2.545% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -307.601% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -112.959% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -60.881% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -163.18% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -362.644% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -139.032% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -313.34% |
| JW Holdings Corporation | 928.07 Billion KRW | 61.09% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 39.891% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 78.369% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 51.757% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -80.348% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -99.769% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -83.915% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 50.287% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -163.18% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 76.156% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 73.744% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 51.757% |
| Yuhan Corporation | 1858.98 Billion KRW | 80.575% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 54.561% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -53.727% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 39.265% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 51.757% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -23.613% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -29.456% |
| CKD Bio Corp. | 160.35 Billion KRW | -125.196% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 31.472% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -56.736% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -80.348% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 58.955% |
| Boryung Corporation | 859.62 Billion KRW | 57.992% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -186.757% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 2.545% |
| JW Lifescience Corporation | 206.86 Billion KRW | -74.566% |